Midomafetamine is under clinical development by Lykos Therapeutics and currently in Phase II for Social Anxiety Disorder (SAD/Social Phobia). According to GlobalData, Phase II drugs for Social Anxiety Disorder (SAD/Social Phobia) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Midomafetamine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Midomafetamine is under investigation for the treatment of schizophrenia, post-traumatic stress disorder (PTSD), social anxiety in autism patients and social anxiety in autistic adults. The drug candidate is psychedelic. It is administered through oral route. It is used as an adjunct to psychotherapy. The drug candidate acts by targeting monoamine oxidase (MAO), sodium dependent dopamine transporter (SLC6A3) and sodium dependent noradrenaline transporter (SLC6A2).
Lykos Therapeutics overview
Lykos Therapeutics, a subsidiary of Multidisciplinary Association for Psychedelic studies, is a biotechnology research company engaged in developing novel therapeutics for the treatment of mental health conditions. It is headquartered in San Jose, California, the US.
For a complete picture of Midomafetamine’s drug-specific PTSR and LoA scores, buy the report here.